Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice.
- Author:
Ho Sup LEE
1
;
Chang Ki MIN
Author Information
- Publication Type:Clinical Trial ; Review
- Keywords: Multiple myeloma; Maintenance; Consolidation; Proteasome inhibitors; Immunologic factors
- MeSH: Glucocorticoids; Humans; Immunologic Factors; Multiple Myeloma*; Plasma; Proteasome Inhibitors; Recurrence; Stem Cell Transplantation; Survival Rate
- From:The Korean Journal of Internal Medicine 2016;31(5):809-819
- CountryRepublic of Korea
- Language:English
- Abstract: Multiple myeloma is an incurable malignant plasma cell-originating cancer. Although its treatment outcomes have improved with the use of glucocorticoids, alkylating drugs, and novel agents, including proteasome inhibitors (bortezomib and carfilzomib) and immunomodulatory drugs (thalidomide, lenalidomide, and pomalidomide), relapse remains a serious problem. Strategies to improve outcomes following autologous stem cell transplantation and frontline treatments in non-transplant patients include consolidation to intensify therapy and improve the depth of response and maintenance therapy to achieve long-term disease control. Many clinical trials have reported increased progression-free and overall survival rates after consolidation and maintenance therapy. The role of consolidation/maintenance therapy has been assessed in patients eligible and ineligible for transplantation and is a valuable option in clinical trial settings. However, the decision to use consolidation and/or maintenance therapy needs to be guided by the individual patient situation in actual clinical practice. This review analyzes the currently available evidence from several reported clinical trials to determine the optimal consolidation and maintenance therapy in clinical practice.
